Live from the NIH registry
Studies recruiting near Portland right now
Top 25 of 167 recruiting studies, sorted by proximity — each links to its official registry page
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Maine Eye Center — Portland, Maine (1.5 mi)
· Sponsor: Genentech, Inc.
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Phase 3
Interventional 904 participants sought
New England Cancer Specialists ( Site 0132) — Westbrook, Maine (5.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
Non-Traumatic Subarachnoid Hemorrhage
Phase 4
Interventional 20 participants sought
MaineHealth — Portland, Maine (1.5 mi)
· Sponsor: Madeleine Puissant
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ganglioneuroblastoma, Nodular, Neuroblastoma
Phase 3
Interventional 478 participants sought
Maine Children's Cancer Program — Scarborough, Maine (7.3 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
Phase 2
Interventional 93 participants sought
MaineHealth Maine Medical Center - Portland — Portland, Maine (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Phase 3
Interventional 558 participants sought
New England Cancer Specialists — Westbrook, Maine (5.0 mi)
· Sponsor: BioNTech SE
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Cancer
Phase 1, Phase 2
Interventional 148 participants sought
Maine Medical Center — Scarborough, Maine (7.3 mi)
· Sponsor: Alliance Foundation Trials, LLC.
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Phase 3
Interventional 255 participants sought
MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine (7.3 mi)
· Sponsor: National Cancer Institute (NCI)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
MaineHealth Maine Medical Center - Portland — Portland, Maine (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer, Early Breast Cancer
Phase 3
Interventional 4,300 participants sought
Research Site — Scarborough, Maine (7.3 mi)
· Sponsor: AstraZeneca
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Community-acquired Pneumonia
Phase 3
Interventional 4,000 participants sought
Maine Medical Centre — Portland, Maine (1.5 mi)
· Sponsor: University of Manitoba
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Phase 3
Interventional 1,123 participants sought
Maine Medical Center - Scarborough Campus ( Site 6042) — Scarborough, Maine (7.3 mi)
· Sponsor: Merck Sharp & Dohme LLC
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
MaineHealth Maine Medical Center - Portland — Portland, Maine (1.5 mi)
· Sponsor: NRG Oncology
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Phase 3
Interventional 62 participants sought
Maine Children's Cancer Program — Scarborough, Maine (7.3 mi)
· Sponsor: Children's Oncology Group
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 2
Interventional 80 participants sought
Maine Children's Cancer Program — Scarborough, Maine (7.3 mi)
· Sponsor: Children's Oncology Group
Clinical Outcome Measure at Stryker Spine
Degenerative Disc Disease, Degenerative Scoliosis
N/A
Observational 5,222 participants sought
MaineHealth Neurosurgery and Spine — Scarborough, Maine (7.3 mi)
· Sponsor: VB Spine, LLC
IMPRoving Outcomes in Vascular DisEase - Aortic Dissection
Type B Aortic Dissection
N/A
Interventional 1,100 participants sought
MaineHealth — Scarborough, Maine (7.3 mi)
· Sponsor: Duke University
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine (2.9 mi)
· Sponsor: Wake Forest University Health Sciences
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Breast Cancer, Locally Advanced Breast Cancer
Phase 3
Interventional 1,000 participants sought
Clinical Trial Site — Scarborough, Maine (7.3 mi)
· Sponsor: Olema Pharmaceuticals, Inc.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non Small Cell Lung Cancer
Phase 3
Interventional 780 participants sought
New England Cancer Specialists ( Site 0095) — Westbrook, Maine (5.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
Leukemia, Myelodysplastic Syndromes
N/A
Observational 300 participants sought
Maine Medical Center — Portland, Maine (1.5 mi)
· Sponsor: Dana-Farber Cancer Institute
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian Neoplasms, Fallopian Tube Neoplasms
Phase 3
Interventional 1,630 participants sought
Maine Medical Center - Scarborough Campus — Scarborough, Maine (7.3 mi)
· Sponsor: Eli Lilly and Company
Fabry Disease Registry & Pregnancy Sub-registry
Fabry Disease
N/A
Observational 9,000 participants sought
Maine Medical Partners Pediatric Specialty Care- Site Number : 840064 — Portland, Maine (1.5 mi)
· Sponsor: Genzyme, a Sanofi Company
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Phase 1
Interventional 47 participants sought
MaineHealth Maine Medical Center - Portland — Portland, Maine (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Gaucher Disease, Cerebroside Lipidosis Syndrome
N/A
Observational 12,000 participants sought
Maine Medical Partners Pediatric Specialty Care- Site Number : 840064 — Portland, Maine (1.5 mi)
· Sponsor: Genzyme, a Sanofi Company